Sign Up to like & get recommendations! 2
Published in 2023 at "JAMA dermatology"
DOI: 10.1001/jamadermatol.2023.1105
Abstract: This cohort study investigated the association between treatment of dermatomyositis with intravenous immunoglobulin and thromboembolic events. read more here.
Sign Up to like & get recommendations! 2
Published in 2023 at "Thrombosis and Haemostasis"
DOI: 10.1055/a-2015-8597
Abstract: Patients with cancer associated venous thromboembolism (VTE) have a higher risk of recurrent VTE than those without cancer and require long-term anticoagulation, but these patients are also at higher risk of anticoagulant-related bleeding because of… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Medicine"
DOI: 10.1097/md.0000000000016514
Abstract: Abstrct The purpose of this study was to evaluate the efficacy and safety of rivaroxaban for the treatment of cancer-associated venous thromboembolism (VTE). We performed a retrospective chart review of cancer patients with a pulmonary… read more here.
Sign Up to like & get recommendations! 0
Published in 2018 at "European Journal of Haematology"
DOI: 10.1111/ejh.13074
Abstract: Low molecular weight heparin (LMWH) is the guideline‐endorsed treatment for cancer‐associated venous thromboembolism (cVTE). Study objectives were to compare the efficacy and safety of rivaroxaban and enoxaparin in cVTE. read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Journal of Thrombosis and Haemostasis"
DOI: 10.1111/jth.15818
Abstract: Data on the population‐based incidence of cancer‐associated venous thromboembolism (VTE) from racially diverse populations are limited. read more here.
Sign Up to like & get recommendations! 0
Published in 2018 at "BMJ Evidence-Based Medicine"
DOI: 10.1136/bmjebm-2018-111007
Abstract: Commentary on : Raskob GE, van Es N, Verhamme P, et al . Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med . 2018 Feb 15;378:615–624. Low-molecular-weight heparin (LMWH) is the standard of… read more here.
Sign Up to like & get recommendations! 0
Published in 2021 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/1078155220984371
Abstract: Cancer-associated venous thromboembolism (VTE) is a common complication of malignancy. Patients with cancer exhibit risk factors for both recurrent VTE and major or minor bleeding. Direct oral anticoagulants (DOACs) are an attractive treatment option; however,… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2022008160
Abstract: Anticoagulant treatment of pediatric cancer–associated venous thromboembolism (VTE) has not been prospectively evaluated. Management of anticoagulation for cancer-associated VTE is often challenged by drug interactions and treatment interruptions. A total of 56 of the 500… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Translational Cancer Research"
DOI: 10.21037/tcr.2019.09.55
Abstract: Low molecular weight heparin (LMWH) is the first-line therapy in acute cancer-associated venous thromboembolism (CAT). However, heparin-induced thrombocytopenia (HIT) is a life-threatening adverse drug reaction that occurs in anticoagulation therapy with LMWH. This article reports… read more here.